GLP-1-based weight-loss medications, promoted both by pharma companies with careful regulatory compliance and by telehealth providers through direct-to-consumer campaigns, face contrasting advertising landscapes. Celebrity endorsements, such as Serena Williams’ GLP-1 ad for telehealth provider Ro, highlight less regulated promotion channels, which avoid detailed side-effect disclosures. Meanwhile, pharmaceutical ads for drugs like Novo Nordisk’s Wegovy incorporate extensive risk information due to FDA rules. The differing approaches raise concerns about consumer understanding, safety communications, and potential regulatory reforms targeting pharmaceutical advertising practices.